on top statins

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsAll cause death

cardiovascular prevention  

alirocumab  
ODYSSEY OUTCOMES, 2018      NCTalirocumabplacebo (on top statins)Low risk of bias conclusive-13%-15%
evolocumab  
FOURIER, 2017      NCTevolocumabplacebo (on top statins)Low risk of bias conclusive-20%4%
ezetimibe  
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-6%-1%